Registry for young adults diagnosed with pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to collect clinical, pathological, and genomic data, along with survival outcomes, from individuals diagnosed with pancreatic ductal adenocarcinoma (PDAC) at or before the age of 55. By gathering this information, the registry seeks to facilitate future clinical trials that can utilize both prospective and retrospective data. The focus is on understanding the unique characteristics and outcomes of younger patients with this aggressive cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≤55 years old at the time of diagnosis of pancreatic cancer
* Age ≥ 18 years
* Written informed consent obtained.

Exclusion Criteria:

* Any pancreatic neoplasm other than pancreatic cancer (e.g. cholangiocarcinoma, ampullary cancer,duodenal cancer, non-invasive mucinous cystic neoplasm, pancreatic intra-epithelial neoplasia 1 and 2, non-invasive intraductal papillary mucinous neoplasm, serous cystic neoplasm, pseudo papillary solid tumor, neuroendocrine tumor)
* Absence of informed consent.
* Age \< 18 years or \> 55 years old at the time of diagnosis of pancreatic cancer

Where it's running

• AOUI Verona
  Verona, Italy Recruiting

Study contacts

• Study coordinator: Fabio Casciani
• Email: fabio.casciani@univr.it
• Phone: 0458124671

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-assisted 4D PET imaging to detect early pancreatic cancer lesions

  This study tests whether AI-assisted 4D long-axial PET imaging with FDG and FAPI can help detect early PDAC lesions in patients with suspected pancreatic tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07925125

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Biophotonic blood test to spot pancreatic cancer risk in at‑risk adults

  A blood test using light-based technology is being tested to see if it can predict pancreatic cancer development in people at risk, and also check how well treatments work for those affected.

  Recruiting Fondazione Policlinico Universitario Campus Bio-Medico · Rome, Italy · NCT07659639

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Personalised Functional Profiling in colorectal cancer and pancreatic cancer

  This study tests a personalized drug-profiling approach using patient tumors to see if lab drug responses match actual patient outcomes in colorectal cancer and pancreatic cancer.

  Recruiting Luxembourg Institute of Health · Luxembourg, Luxembourg · NCT07500259

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.